These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37262309)

  • 1. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
    Schäkel K; Reich K; Asadullah K; Pinter A; Jullien D; Weisenseel P; Paul C; Gomez M; Wegner S; Personke Y; Kreimendahl F; Chen Y; Angsana J; Leung MWL; Eyerich K
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2016-2027. PubMed ID: 37262309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
    Eyerich K; Asadullah K; Pinter A; Weisenseel P; Reich K; Paul C; Sabat R; Wolk K; Eyerich S; Lauffer F; Angsana J; Taut FJH; Kohler K; Chen Y; Sendecki J; Leung MWL; Wegner S; Personke Y; Gomez M; Krüger N; Tabori S; Schäkel K
    JAMA Dermatol; 2024 Jul; ():. PubMed ID: 39083288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
    Reich K; Gordon KB; Strober B; Langley RG; Miller M; Yang YW; Shen YK; You Y; Zhu Y; Foley P; Blauvelt A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2393-2400. PubMed ID: 35920762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
    Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
    J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.
    Javaid K; Andruszka C
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e302-e303. PubMed ID: 37907280
    [No Abstract]   [Full Text] [Related]  

  • 12. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
    Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
    Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
    J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
    Diels J; Thilakarathne P; Cameron C; McElligott S; Schubert A; Puig L
    Br J Dermatol; 2020 Aug; 183(2):276-284. PubMed ID: 31652347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.